Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Philippe Shils

Physician Assistant Decatur, IL Physician Assistant

NPI 1649364290 CMS profile 10434576

1800 E Lake Shore Drive, Decatur, IL 62521

Open in the dashboard

General payments

$13,373

834 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philippe Shils of Decatur, IL is reported in the CMS Open Payments database as having received $13,373 across 834 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,682 153
2024 General $2,782 165
2023 General $2,459 158
2022 General $2,649 169
2021 General $2,802 189

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philippe Shils
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Philippe Shils were reported at $2,682. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Philippe Shils Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,802 $132 $37–$438 $132
2022 $2,649 $155 $48–$522 $149
2023 $2,459 $167 $52–$557 $160
2024 $2,782 $178 $55–$600 $164
2025 $2,682 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,323 88 payments
  2. Amgen Inc. $1,165 70 payments
  3. AstraZeneca Pharmaceuticals LP $1,157 62 payments
  4. Lilly USA, LLC $943 57 payments
  5. Novo Nordisk Inc $860 69 payments
  6. Pfizer Inc. $777 54 payments
  7. GlaxoSmithKline, LLC. $751 51 payments
  8. Novartis Pharmaceuticals Corporation $725 49 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $611 38 payments
  10. Astellas Pharma US Inc $452 22 payments
  11. Other $4,611 274 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,268 832 payments
  2. Education $106 2 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $751 51 payments
  2. EVENITY $562 35 payments
  3. LEQVIO $519 35 payments
  4. MOUNJARO $508 28 payments
  5. Otezla $501 29 payments
  6. BREZTRI $494 21 payments
  7. FARXIGA $482 20 payments
  8. NURTEC ODT $482 31 payments
  9. JARDIANCE $461 28 payments
  10. Repatha $461 27 payments
  11. Other $11,441 729 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,239

Median for Physician Assistant: 241

Drug cost

$45,056

Median for Physician Assistant: $4,110

Branded share of claims

18.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $25,051
Jardiance Empagliflozin Brand 13 $9,694
Albuterol Sulfate Hfa Albuterol Sulfate Brand 60 $1,409
Pantoprazole Sodium Generic 128 $1,003
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 51 $936
Ventolin Hfa Albuterol Sulfate Brand 13 $708
Montelukast Sodium Generic 43 $617
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 11 $518
Doxycycline Hyclate Generic 77 $474
Amlodipine Besylate Generic 68 $415

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$38,759

Of which drugs: $1,878

Medicare patients

456

Average age 75

Services billed

865

283 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 36%
Diabetes 31%
Atrial fibrillation 22%
Heart failure 21%
Chronic kidney disease 21%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,555

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$229 — —
Wegovy
$183 — —
VRAYLAR
$153 — —
UBRELVY
$147 — —
AIRSUPRA
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

834 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record